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Abstract
Objective—While it is now recognized that psychotic experiences (PEs) are associated with an 
increased risk of later mental disorders, we lack a detailed understanding of the reciprocal time-
lagged relationships between first onsets of PEs and mental disorders.
Methods—The WHO World Mental Health (WMH) surveys assessed lifetime prevalence and 
age-of-onset of PEs and 21 common DSM-IV mental disorders among 31,261 adult respondents 
from 18 countries.
Results—Temporally primary PEs were significantly associated with subsequent first onset of 8 
of the 21 mental disorders (major depressive disorder, bipolar disorder, generalized anxiety 
disorder, social phobia, post-traumatic stress disorder, adult separation anxiety disorder, bulimia 
nervosa, alcohol abuse), with ORs (95%CI) ranging from 1.3 (1.2–1.5; major depressive disorder) 
to 2.0 (1.5–2.6; bipolar disorder). In contrast, 18 of 21 primary mental disorders were significantly 
associated with subsequent first onset of PEs, with ORs (95% CI) ranging from 1.5 (1.0–2.1; 
childhood separation anxiety disorder) to 2.8 (1.0–7.8; anorexia nervosa).
Conclusions—While temporally primary PEs are associated with an elevated risk of several 
subsequent mental disorders, we found that most mental disorder are associated with an elevated 
risk of subsequent PEs. Further investigation of the underlying factors accounting for these time-
order relationships might shed light on the etiology of PEs.
Introduction
A recent study based on data from 18 countries participating in the WHO World Mental 
Health Surveys (WMH) found that lifetime prevalence of any psychotic experience (PE) 
among adults was 5.8% (standard error [se] = 0.2) (1). These WMH estimates were broadly 
consistent with PE prevalence estimates in other population-based studies (2, 3). The 
relatively high lifetime prevalence of PEs is much higher than the 0.7% mean morbid risk 
for schizophrenia (4) and raises important questions about the clinical significance of PEs 
with respect to the risk of psychosis and mental disorders in general.
There is solid evidence from prospective studies that PEs are associated with an increased 
risk of later psychotic disorders (5–7). In addition, there is some evidence that PEs are 
associated with increased risk of subsequent non-psychotic mental disorders (8), but this 
field of research has for the most part examined associations between lifetime PEs and 
lifetime common mental disorders regardless of temporal priority. For example, there is 
evidence linking the lifetime prevalence of PE with high prevalence of depression and 
anxiety disorders (9–12), substance use disorders (13), and behavioural disorders (14). 
Despite these clues, there is a lack of empirical data on whether temporally primary common 
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mental disorders are associated with an increased risk of subsequent first onset of PEs, and 
conversely, which mental disorders are predicted by pre-existing PEs.
We had the opportunity to carry out a preliminary exploration of the bidirectional time-
lagged associations between PEs and mental disorders using retrospective age-of-onset 
(AOO) reports within the WMH surveys. The aims of this study were to explore the 
associations of (a) temporally primary PEs with the subsequent onset of mental disorders 
and (b) temporally primary mental disorders with the subsequent onset of PEs.
METHOD
Samples
The WMH surveys are a coordinated set of community epidemiological surveys 
administered in probability samples of the household population in countries throughout the 
world (www.hcp.med.harvard.edu/WMH) (15). Eighteen of the 29 WMH surveys completed 
up to now included a Psychosis Module. These 18 countries are distributed across North and 
South America (Colombia, Mexico, Peru, Sao Paulo in Brazil, USA); Africa (Nigeria); the 
Middle East (Iraq, Lebanon); Asia (Shenzhen in the People’s Republic of China); the South 
Pacific (New Zealand); and Europe (Belgium, France, Germany, Italy, the Netherlands, 
Portugal, Romania, Spain). All 18 surveys were based on multi-stage, clustered area 
probability household sampling designs (Supplementary Table S1). Individual country 
sample sizes ranged from 301 in France to 7 263 in New Zealand. The weighted average 
response rate across all 18 surveys was 72.1%.
In keeping with previous epidemiological studies of PEs (1, 13, 16, 17), we made the a priori 
decision to exclude individuals who had PEs but who also screened positive for possible 
schizophrenia/psychosis or manic-depression/mania (i.e. respondents who (a) reported (1) 
schizophrenia/ psychosis or (2) manic-depression/mania in response to the question “What 
did the doctor say was causing (this/these) experiences?”; and/or (b) those who ever took 
any antipsychotic medications for these symptoms). This resulted in the exclusion of 140 
respondents (0.4% of all respondents), leaving 31 261 respondents for this study (see Table 
S1).
Procedures
All surveys were conducted in respondents’ homes by trained lay interviewers. Informed 
consent was obtained before beginning interviews in all countries. Procedures for obtaining 
informed consent, ethical approvals and protecting individuals were monitored for 
compliance by the institutional review boards of the collaborating organisations in each 
country (18). Standardised interviewer training and quality control procedures were used 
consistently in the surveys. Full details of these procedures are described elsewhere (18, 19).
All WMH interviews had two parts. Part I, administered to all respondents, contained 
assessments related to core mental disorders. Part II included additional information relevant 
to a wide range of survey aims, including assessment of PEs. All Part I respondents who met 
criteria for any DSM IV mental disorder as well as a probability sample of other respondents 
were administered Part II. Within the different sites, items related to PEs were either 
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administered to all respondents or a random sample of those administered Part II. Part II 
respondents were weighted by the inverse of their probability of selection for Part II to 
adjust for differential sampling. Additional weights were used to adjust for differential 
probabilities of selection within households, nonresponse, and to match the samples to 
population socio-demographic distributions. The weighted data are analysed here.
Data collection and Data items
The diagnostic instrument used in the WMH surveys was the WHO Composite International 
Diagnostic Interview (CIDI) (20), a validated fully-structured diagnostic interview (http://
www.hcp.med.harvard.edu/wmhcidi/instruments_download.php) designed to assess the 
prevalence and correlates of a wide range of mental disorders according to the definitions 
and criteria of both the DSM-IV and ICD-10 diagnostic systems. WHO translation, back-
translation, and harmonisation protocols were used to adapt the CIDI for use in each 
participating country (21).
Psychotic experiences (PEs)—The CIDI Psychosis Module included questions about 6 
PE types – 2 related to hallucinations (HEs: visual hallucinations, auditory hallucinations) 
and 4 related to delusions (DEs: thought insertion/withdrawal, mind control/passivity, ideas 
of reference, plot to harm/follow) (Supplementary Material Tables S2a and S2b). The 
module began by asking respondents if they ever experienced the PEs (e.g., “Have you ever 
seen something that wasn’t there that other people could not see?”; “Have you ever heard 
any voices that other people said did not exist?” etc). Positive responses were then probed to 
determine if the reported PEs ever occurred when the person was ‘not dreaming, not half-
asleep, or not under the influence of alcohol or drugs’ (this probe question was included in 
the main question in European Study of the Epidemiology of Mental Disorders (ESEMeD) 
countries). Respondents who reported PEs were then asked a further probe question about 
the age-of-onset (AOO) of PEs (i.e., How old were you the very first time (this/either of 
these things/any of these things) happened to you?). In the 8.0% of cases where PE AOO 
was missing, we used imputation to assign predicted values based on a set of predictors that 
included all the variables in the substantive models (22). Key summary statistics (n, mean, 
SE, median, IQR) for the observed data (without imputation) and the entire dataset after 
imputation are shown in Supplementary Material Table S4.
DSM-IV Mental disorders—The WMH survey version of the CIDI assessed lifetime 
history of 21 mental disorders considered in this paper including mood disorders (major 
depressive disorder, bipolar disorders); anxiety disorders (panic disorder, generalized anxiety 
disorder, specific phobia, social phobia, agoraphobia without panic, post-traumatic stress 
disorder (PTSD), separation anxiety disorder further divided into childhood, and adult 
separation anxiety disorders); impulse control disorders (intermittent explosive disorder, 
attention deficit disorder, oppositional defiant disorder, conduct disorder); eating disorder 
(anorexia nervosa, bulimia nervosa, and binge eating disorder); and substance use disorders 
(alcohol abuse, alcohol dependence, drug abuse, and drug dependence). The disorders that 
require childhood onset (e.g., attention deficit disorder, oppositional defiant disorder, 
conduct disorder, separation anxiety disorder) were included in Part II and are limited to 
respondents in the age range 18–39/44 due to concerns about recall bias among older 
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respondents (23). All other disorders were assessed for the full sample age range. Clinical 
reappraisal studies indicate that lifetime diagnoses based on the CIDI have good 
concordance with diagnoses based on blinded clinical interviews (24).
In keeping with previous research, standardised diagnostic hierarchy rules among the 
disorders assessed were applied where appropriate (25). When applied, a person is excluded 
from a diagnosis, even though he/she has sufficient symptoms to meet criteria, because the 
person may have another disorder that is thought to account for those symptoms. For 
example, someone who has alcohol dependence cannot be diagnosed with alcohol abuse as 
dependence is a more severe diagnosis. Therefore, alcohol abuse with hierarchy means it 
cannot occur exclusively during episodes of alcohol dependence. However, given that the 
analysis was based on a person-year data array (see below), these diagnoses can change 
within persons over time. For example, a respondent with an onset of alcohol abuse at age 18 
and alcohol dependence at 22 would be coded as having alcohol abuse over the years 18–21 
and as having alcohol dependence beginning at age 22.
Statistical Analysis
Discrete-time survival analyses (26) with person-year as the unit of analysis and time-
varying measures for prior onset of other mental disorders were used to examine the 
predictive associations of temporally prior disorders with the subsequent onset of each 
mental disorder considered in the analysis. A person-year dataset was created such that each 
year in the life of each respondent (up to and including the age of onset of the outcome 
disorder or their age at interview, whichever came first) was treated as a separate 
observational record. We estimated survival models that examined bivariate associations 
between PEs and only one common mental disorder at a time (with adjustment for age-
cohorts, sex, person-year, education, marital and employment status, and country) as well as 
multivariate models that included information on all temporally primary common mental 
disorders to predict the outcome disorder. The latter models included measures for both type 
and number of prior mental disorders. In the case of multivariate models of the associations 
between temporally primary PEs and later disorders, we controlled for the association of 
other temporally primary disorders, again including measures for both type and number of 
these disorders, in order to determine if significant net associations existed between 
temporally primary PEs and subsequent onsets of the outcome disorders. Measures of 
number of temporally primary disorders (e.g., dummy predictors for exactly 2, exactly 3, 
and more than 3 such disorders) provide a coarse characterization of the non-additive 
associations among the predictor disorders. Previous research has shown that the coefficients 
associated with these predictors are for the most part negative and significant (27), indicating 
the presence of “sub-additive” interactions among comorbid disorders. The latter suggests 
that the predictive associations of having multiple temporally prior disorders increase at a 
decreasing rate as the number of such disorders increases. A more detailed discussion of the 
logic of these models is presented elsewhere (27).
All survival coefficients and standard errors were exponentiated to create odds-ratios with 
95% confidence intervals. Because the WMH survey data were based on geographically 
clustered and weighted data, standard errors (SE) were estimated with the Taylor series 
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linearization method (28) using SUDAAN software (29) to adjust for weighting and 
clustering. Statistical significance was evaluated using F tests or Wald χ2 tests based on 
design-corrected coefficient variance–covariance matrices. Statistical significance was 
evaluated consistently using two-tailed .05-level tests.
RESULTS
Lifetime prevalence of DSM-IV mental disorders among respondents with and without 
psychotic experiences
We first examined lifetime prevalence of mental disorders among respondents with and 
without PEs regardless of the temporal order of PE and mental disorders (Table 1). 
Compared to those with no PEs, those with PEs had significantly higher odds of having 20 
of the 21 mental disorders examined (based on lifetime prevalence). Odds Ratios [OR] and 
95% Confidence Intervals [95%CI] ranged from 1.6 (1.2–2.1) for Drug Abuse to 3.6 (2.6–
5.0) for Bulimia nervosa.
Temporal priorities between onset ages of PEs and DSM-IV mental disorders
Table 2 examines the temporal sequence between ages of onset of PEs compared to mental 
disorders within the subset of respondents having both PEs and particular mental disorders. 
We show the proportion of respondents with (a) PE onset prior to particular mental disorder 
onset, (b) PE onset in the same year with the mental disorder, and (c) PE onset after the 
mental disorder onset, and then test if the proportions with PE onset before or after mental 
disorders significantly differ (i.e., those with onset in the same year were excluded from this 
comparison). While the overall findings indicate that most PEs have their onset after mental 
disorders, this pattern varies between diagnoses. For example, the proportion of respondents 
with PE onset prior to the onset of bipolar disorders was significantly higher (54%) than the 
proportion with PE onset after the onset of bipolar disorder (39%) (χ2 = 6.0, p <.02), while 
there was no difference of PE onset with respect to the onset of depressive disorders (χ2 = 
0.1, p=.767). By contrast, for many disorders (e.g. 4 of 8 anxiety disorders, and all of the 
impulse control disorders), higher proportions of respondents reported PE onsets after the 
onset of the mental disorders of interest.
Time-lagged associations between lifetime PEs and subsequent onset of mental disorders
A limitation of the results in Table 2 is that they do not take into consideration differences in 
the age-of-onset distributions of the different disorders in relation to the age of onset 
distribution of PEs. This issue is addressed in Table 3 (a more detailed presentation of these 
analyses can be found in Supplementary material Table S4), where we show the results from 
bivariate and multivariate models of the associations between PEs and subsequent mental 
disorders (i.e. the temporal order requires the onset of PE to precede the onset of the mental 
disorder of interest). In the bivariate analysis, the associations are adjusted for age-cohort, 
gender, person-year, employment status and country as well as time-varying education and 
marital status (without mental disorder co-morbidity). In these models, preceding PEs were 
significantly associated with increased odds for 16 of the 21 mental disorders. It is 
noteworthy that 3 of the 5 remaining disorders have childhood onsets by definition (AHHD, 
conduct disorder, childhood separation anxiety disorder). These three disorders also had 
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elevated ORs with temporally prior PEs in the range 1.7–2.5, but none of these elevated ORs 
was statistically significant due to the rarity of PEs occurring prior to the onsets of these 
disorders. In the multivariate models, we further adjusted for temporally prior comorbid 
mental disorders (i.e. adjusting for comorbid mental disorders that had onsets prior to the 
onset of the mental disorder of interest, but not necessarily prior to the onset of PEs). Those 
with PEs were significantly more likely to subsequently experience 8 of 21 disorders (major 
depressive disorder, bipolar disorder, generalized anxiety disorder, social phobia, post-
traumatic stress disorder, adult separation anxiety disorder, bulimia nervosa, alcohol abuse), 
with ORs (95%CI) ranging from 1.3 (1.2–1.5) for major depressive disorder to 2.0 (1.5–2.6) 
for bipolar disorder. In the multivariate models shown in Supplementary Table S4, the ORs 
associated with number of temporally prior disorders were for the most part lower than 1.0, 
indicating a general pattern of sub-additive interactions whereby the incremental association 
of each additional temporally primary disorder lessens in magnitude as the number of such 
disorders increases.
Time-lagged associations between lifetime mental disorders and subsequent onset of PEs
Next we examined the associations between preceding mental disorders and the subsequent 
onset of PEs (Table 4). In bivariate models, 20 of the 21 mental disorders were significantly 
associated elevated odds of subsequent PEs (drug abuse was the only disorder not associated 
with later PE onset – note that our study excluded PEs that were experienced under the 
influence of alcohol or drugs). In multivariate models, we found that 18 of the 21 mental 
disorders were significantly associated with the later onset of PEs, with ORs (95%CI) 
ranging from 1.5 (1.0–2.1) for associated with the later onset of PEs, with ORs (95%CI) 
ranging from 1.5 (1.0–2.1) for childhood separation anxiety disorder to 2.8 (1.0–7.8) for 
anorexia nervosa. As with the previous models predicting mental disorders after temporally 
primary PEs (Supplementary Table S4), the ORs (95% CIs) associated with number of 
temporally primary mental disorders (2, 3, 4, 5+) were for the most part less than 1, 
confirming the existence of sub-additive interactions among mental disorders in predicting 
first onset of temporally secondary PEs. The joint associations of all the number-of-disorder 
coefficients were significant (χ24 = 31.1, p <.001).
The key findings from Tables 3 and 4 are summarized in the Figure, which allows quick 
comparisons between; (a) the ORs for the onset of mental disorders after the onset of PEs, 
with (b) the ORs for the onset of PEs after the onset of mental disorders, when sorted by 
mental disorder type.
DISCUSSION
This large, cross-national study demonstrates that individuals with PEs are at increased risk 
of experiencing a wide range of mental disorders at some stage in their life compared to 
other people in the population. The mental disorders include mood, anxiety, impulse control, 
and eating and substance-use disorders. The lack of specificity in these associations even in 
multivariate models is consistent with the hypothesis that PEs may be non-specific markers 
of a wide range of mental disorders (30).
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Our temporally-ordered analyses have provided new insights into the bidirectional 
relationship between PEs and mental disorders. We found a strikingly consistent increased 
risk of PE onset after nearly all of the mental disorders we examined. That is, most mental 
disorders were associated with increased risk of subsequent PEs even in multivariate models. 
Of the 21 disorders examined in this study, only three externalizing disorders did not 
significantly predict subsequent PEs in the multivariate model (i.e. conduct disorder, drug 
abuse, drug dependence).
We also found that the onset of PEs predicted significantly increased risk of subsequent 
major depressive disorder, bipolar disorder, generalized anxiety disorder, social phobia, post-
traumatic stress disorder, adult separation anxiety disorder, bulimia nervosa, and alcohol 
abuse. Thus, in addition to risk of psychotic disorders (8), an increased risk of subsequent 
mood disorders, some anxiety disorders, eating disorders and substance use disorders are 
seen after PE onset. These findings call into the question the specificity of the association 
between PEs and psychotic disorders (31).
Curiously, in the analyses of PEs predicting subsequent onset of mental disorders, PEs 
predicted none of the four impulse control disorders and only one of the four substance-use 
disorders (alcohol abuse), while PEs did predict a number of the mood and anxiety 
disorders. These findings reveal that the temporal relationships between PEs and mental 
disorders are bidirectional for some disorders. Importantly, this is not due to the different 
age-of-onset distributions of these disorders, as pervasively significant time-lagged bivariate 
associations were found across disorders. The differential came only when we estimated 
multivariate models in which we can see unique incremental associations of a single 
temporally primary disorder with a temporally secondary disorder net of the additive effects 
of comorbid disorders. Taking into account the temporal order of the variables of interest, 
sub-additive associations between comorbid mental disorders and PEs were identified in 
both analyses (i.e. this feature is also bidirectional).
While the current study has many strengths (e.g. large sample size, range of countries, 
uniform methodology for data collection), it also has several important limitations. We relied 
on lay interviewers to administer the questionnaire. We excluded those who were screen-
positive for possible psychotic disorders (based on self-report, use of antipsychotic 
medications to treat PEs). However, we did not have access to valid measures of clinical 
psychotic disorders, an important consideration for understanding the utility of PEs as 
predictors of later psychotic disorders. We relied on retrospective reports about age of onset, 
which might have led to a recall bias despite the use of special age of onset probes in the 
CIDI that have been shown to improve the accuracy of retrospective age of onset reporting 
(32). And we estimated models that assumed that predictive associations were additive and 
independent of age-of-onset, time-since-onset, and, in the models for temporally primary 
PEs predicting later disorders, interactions of PEs with disorders occurring prior to the onset 
of the outcome disorders. More complex models that relaxed these simplifying assumptions 
might well shed light on the asymmetries found here in the time-lagged multivariate 
associations between PEs and other disorders. Large prospective surveys would be needed to 
confirm the temporal order between the variables examined in this study. An additional 
caution is that even in the presence of unequivocal information on temporal ordering of 
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onsets, we cannot infer causality, as common unmeasured causes may influence associations 
between temporally primary and secondary disorders (see below).
Future directions
Our findings provide a heuristic framework for the generation of new hypotheses related to 
PEs, which we will explore in subsequent studies. For example, it will be of interest to see 
what proportion of early versus late onset PEs arise (a) de novo, or (b) following the onset of 
a mental disorder, as well as the extent to which early-onset PEs and PEs of different types 
(e.g., DEs vs. HEs) predict the subsequent first onset of different types of mental disorders 
and do so differentially as a complex function of age-of-onset, time-since-onset, and 
existence of complex comorbidities. It is also feasible that an underlying diathesis might 
lead to both an increased risk of PE and an increased risk of mental disorders (regardless of 
the temporal order of these variables). It is plausible that familial/genetic factors and/or 
adverse early life exposures (e.g. childhood adversities, cannabis use) could lead to both an 
increased risk of later mental disorders and an increased risk of PEs (33–35). The 
comprehensive nature of the WMH survey will allow us to explore these and other related 
hypotheses in future analyses, albeit within the context of the inherent limitations of cross-
sectional data assessed with fully-structured diagnostic interviews.
CONCLUSIONS
Individuals with PEs were significantly more likely to have subsequent first onsets of 8 of 21 
common mental disorders (major depressive disorder, bipolar disorder, generalized anxiety 
disorder, social phobia, post-traumatic stress disorder, separation anxiety disorder (adult), 
bulimia nervosa, alcohol abuse). Conversely, most temporally primary mental disorders were 
significantly associated with the subsequent first onset of PEs. Our findings have important 
implications for the understanding of how PEs fit into the structure of psychopathology and 
within psychiatric taxonomy. A better understanding of how PEs unfold across the lifespan 
and interact with mental disorder may provide clues to help guide clinical management.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Summary of the bidirectional association between psychotic experiences and mental 
disorders
The Odds ratios were extracted from Tables 3 and 4. Bars to the left (in orange if significant) 
represent the odds ratio of the onset of mental disorders after the onset of Psychotic 
Experiences. Bars to the right (in blue if significant) represent the Odds Ratio for the onset 
of mental disorders after the onset of Psychotic Experiences. Odds ratios for nonsignificant 
associations are shown in light gray.
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Table 3
Associations between lifetime psychotic experiences (PEs) and the subsequent onset of DSM-IV mental 
disorders.
Type of mental disorders
Bivariate modelsa Multivariate modelsb
Odds of disorder Odds of disorder
OR (95% C.I) OR (95% C.I)
I. Mood disorders
  Major depressive disorder with hierarchy 1.6* (1.4–1.9) 1.3* (1.2–1.5)
  Bipolar disorder (broad) 2.7* (2.0–3.5) 2.0* (1.5–2.6)
II. Anxiety disorders
  Panic disorder 2.0* (1.5–2.8) 1.3 (0.9–1.8)
  Generalized anxiety disorder with hierarchy 1.9* (1.5–2.4) 1.4* (1.1–1.8)
  Social phobia 2.0* (1.5–2.7) 1.4* (1.0–1.8)
  Specific phobia 1.0 (0.7–1.5) 0.9 (0.6–1.3)
  Agoraphobia without panic 2.0* (1.2–3.4) 1.2 (0.7–2.1)
  Post-traumatic stress disorder 2.0* (1.6–2.6) 1.3* (1.1–1.7)
  Separation anxiety disorder (Child) 1.7 (0.9–3.2) 1.2 (0.6–2.3)
  Separation anxiety disorder (Adult) 2.7* (1.9–3.6) 1.6* (1.2–2.2)
III. Impulse-control disorders
  Intermittent explosive disorder with hierarchy 1.5* (1.1–2.1) 1.2 (0.9–1.6)
  Attention deficit disorder 2.5 (0.8–7.4) 1.8 (0.6–5.6)
  Oppositional defiant disorder with hierarchy 2.6* (1.2–5.7) 2.1 (0.9–5.0)
  Conduct disorder 1.9 (0.9–4.1) 1.2 (0.5–3.0)
IV. Eating disorders
  Anorexia nervosa 0.9 (0.3–2.8) 0.7 (0.2–2.0)
  Binge eating disorder with hierarchy 1.7* (1.1–2.5) 1.0 (0.7–1.6)
  Bulimia nervosa with hierarchy 3.2* (2.2–4.8) 1.9* (1.2–3.1)
V. Substance-use disorders
  Alcohol abuse with hierarchy 1.7* (1.3–2.3) 1.4* (1.1–1.9)
  Alcohol dependence 1.9* (1.4–2.7) 1.1 (0.8–1.7)
  Drug abuse with hierarchy 1.9* (1.2–2.8) 1.4 (0.9–2.1)
  Drug dependence 2.3* (1.5–3.4) 1.4 (0.9–2.0)
*Significant at the .05 level, 2-sided test.
a
Lifetime PEs was used as a predictor of mental disorder onset in separate discrete-time survival model controlling for age-cohorts, gender, person-
years, country, time-varying education, time-varying marriage and employment status.
b
Lifetime PEs was used as a predictor of mental disorder onset in separate discrete-time survival model including the controls specified above, 
other temporally primary mental disorders and number of temporally primary mental disorders (2,3,4 5+ disorders). Full details of these models are 
shown in Supplementary material Table S4.
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Table 4
Associations between DSM-IV mental disorders and the subsequent onset of psychotic experiences.
Type of mental disorders
Bivariate modelsa Multivariate modelb
OR (95% C.I) OR (95% C.I)
I. Mood disorders
  Major depressive disorder with hierarchy 2.5* (2.1–3.0) 2.2* (1.8–2.7)
  Bipolar disorder (broad) 2.6* (1.9–3.7) 1.9* (1.3–2.9)
II. Anxiety disorders
  Panic disorder 2.5* (1.8–3.4) 1.6* (1.2–2.3)
  Generalized anxiety disorder with hierarchy 2.4* (1.8–3.1) 1.7* (1.2–2.3)
  Social phobia 2.2* (1.8–2.6) 1.5* (1.2–2.0)
  Specific phobia 2.6* (2.2–2.9) 2.2* (1.8–2.7)
  Agoraphobia without panic 2.5* (1.8–3.6) 1.9* (1.3–2.7)
  Post-traumatic stress disorder 2.5* (1.9–3.2) 1.8* (1.3–2.4)
  Separation anxiety disorder (Child) 2.1* (1.5–3.0) 1.5* (1.0–2.1)
  Separation anxiety disorder (Adult) 2.8* (2.1–3.9) 1.9* (1.3–2.8)
III. Impulse-control disorders
  Intermittent explosive disorder with hierarchy 2.4* (1.9–3.0) 1.9* (1.5–2.5)
  Attention deficit disorder 2.7* (2.0–3.8) 1.7* (1.2–2.4)
  Oppositional defiant disorder with hierarchy 3.0* (2.1–4.3) 2.0* (1.3–3.1)
  Conduct disorder 2.5* (1.7–3.7) 1.4 (0.9–2.3)
IV. Eating disorders
  Anorexia nervosa 2.9* (1.1–8.1) 2.8* (1.0–7.8)
  Binge eating disorder with hierarchy 2.2* (1.6–3.2) 1.8* (1.2–2.6)
  Bulimia nervosa with hierarchy 2.7* (1.8–4.2) 1.8* (1.2–3.0)
V. Substance-use disorders
  Alcohol abuse with hierarchy 1.8* (1.4–2.5) 1.8* (1.3–2.5)
  Alcohol dependence 2.4* (1.8–3.3) 2.0* (1.3–2.9)
  Drug abuse with hierarchy 1.5 (1.0–2.3) 1.1 (0.7–1.8)
  Drug dependence 2.6* (1.7–3.9) 1.3 (0.8–2.3)
Joint effect of all types of disorders, χ221, [p-value] 130.4** [<.001]
Difference between types of disorders, χ220, [p-value] 27.9 [0.111]
VI. Number of disorders
  2 disorders 1.0 (0.7–1.3)
  3 disorders 0.5* (0.4–0.8)
  4 disorders 0.4* (0.2–0.8)
  5+ disorders 0.2* (0.1–0.4)
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Type of mental disorders
Bivariate modelsa Multivariate modelb
OR (95% C.I) OR (95% C.I)
Joint effect of all number of disorders, χ24, [p-value] 31.1** [<.001]
*/**Significant at the .05 level, 2-sided test.
a
Each lifetime mental disorder type was used as a predictor of psychotic experiences onset in separate discrete-time survival model controlling for 
age-cohorts, gender, person-years, country, time-varying education, time-varying marriage and employment status.
b
The model was estimated with dummy variables for all temporally primary mental disorders and number of temporally primary mental disorders 
entered simultaneously including the controls specified above.
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